FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990708506> ?p ?o ?g. }

• W2990708506 endingPage "1968" @default.
• W2990708506 startingPage "1957" @default.
• W2990708506 abstract "Abstract Objectives Peficitinib, a novel Janus kinase (JAK) inhibitor, demonstrated promising results in treating RA in phase 3 clinical trials. This in vitro study was undertaken to characterize the pharmacological properties of peficitinib and investigate the involvement of JAK and signal transducer and activator of transcription (STAT) pathways in the pathological processes of SSc, which is also an autoimmune disease. Methods Phosphorylation levels of STAT molecules were assessed in peripheral blood mononuclear cells collected from patients with RA or SSc and healthy subjects, and in skin specimens obtained from 19 patients with SSc. In vitro inhibition of STAT phosphorylation and cytokine/chemokine production by peficitinib, tofacitinib and baricitinib were also characterized. Results Higher spontaneous STAT1 or STAT3 phosphorylation was observed in peripheral T-cells and monocytes from patients with RA and SSc compared with healthy subjects. In skin sections from patients with SSc, phosphorylated STAT3–positive cells were found in almost all cases, irrespective of disease subtype or patient characteristics. Conversely, phosphorylated STAT1-positive cells were observed only in samples from untreated patients with diffuse disease of short duration. Peficitinib inhibited STAT phosphorylation induced by various cytokines, with comparable efficacy to tofacitinib and baricitinib. Peficitinib also suppressed cytokine and chemokine production by peripheral blood mononuclear cells and skin fibroblasts. Conclusion Our results suggest that JAK/STAT pathways are constitutively activated in SSc and RA, and that the JAK inhibitor may represent a novel therapeutic option for SSc." @default.
• W2990708506 created "2019-12-05" @default.
• W2990708506 creator A5007893039 @default.
• W2990708506 creator A5008273074 @default.
• W2990708506 creator A5014913190 @default.
• W2990708506 creator A5015953107 @default.
• W2990708506 creator A5016202197 @default.
• W2990708506 creator A5068524115 @default.
• W2990708506 creator A5073326633 @default.
• W2990708506 creator A5091459931 @default.
• W2990708506 date "2019-11-25" @default.
• W2990708506 modified "2023-10-13" @default.
• W2990708506 title "In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors" @default.
• W2990708506 cites W1973107366 @default.
• W2990708506 cites W1993540575 @default.
• W2990708506 cites W2031544797 @default.
• W2990708506 cites W2058878779 @default.
• W2990708506 cites W2077550414 @default.
• W2990708506 cites W2078981467 @default.
• W2990708506 cites W2081890621 @default.
• W2990708506 cites W2093811818 @default.
• W2990708506 cites W2094808646 @default.
• W2990708506 cites W2097368729 @default.
• W2990708506 cites W2101295768 @default.
• W2990708506 cites W2114633137 @default.
• W2990708506 cites W2118767323 @default.
• W2990708506 cites W2120393706 @default.
• W2990708506 cites W2128952811 @default.
• W2990708506 cites W2152348310 @default.
• W2990708506 cites W2160329190 @default.
• W2990708506 cites W2164096595 @default.
• W2990708506 cites W2201375664 @default.
• W2990708506 cites W2319484775 @default.
• W2990708506 cites W2347093301 @default.
• W2990708506 cites W2508060872 @default.
• W2990708506 cites W2529605118 @default.
• W2990708506 cites W2584816673 @default.
• W2990708506 cites W2612545427 @default.
• W2990708506 cites W2620112591 @default.
• W2990708506 cites W2718751133 @default.
• W2990708506 cites W2747197979 @default.
• W2990708506 cites W2766145635 @default.
• W2990708506 cites W2774773192 @default.
• W2990708506 cites W2783739433 @default.
• W2990708506 cites W2801012323 @default.
• W2990708506 cites W2806476436 @default.
• W2990708506 cites W2810369524 @default.
• W2990708506 cites W2887623230 @default.
• W2990708506 cites W2889154002 @default.
• W2990708506 cites W2903436036 @default.
• W2990708506 cites W2903718987 @default.
• W2990708506 cites W2904631220 @default.
• W2990708506 cites W2904958682 @default.
• W2990708506 cites W2914209107 @default.
• W2990708506 cites W2917539798 @default.
• W2990708506 cites W2943665612 @default.
• W2990708506 cites W2965006635 @default.
• W2990708506 cites W2966824117 @default.
• W2990708506 cites W861551241 @default.
• W2990708506 doi "https://doi.org/10.1093/rheumatology/kez526" @default.
• W2990708506 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7382595" @default.
• W2990708506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31764973" @default.
• W2990708506 hasPublicationYear "2019" @default.
• W2990708506 type Work @default.
• W2990708506 sameAs 2990708506 @default.
• W2990708506 citedByCount "19" @default.
• W2990708506 countsByYear W29907085062020 @default.
• W2990708506 countsByYear W29907085062021 @default.
• W2990708506 countsByYear W29907085062022 @default.
• W2990708506 countsByYear W29907085062023 @default.
• W2990708506 crossrefType "journal-article" @default.
• W2990708506 hasAuthorship W2990708506A5007893039 @default.
• W2990708506 hasAuthorship W2990708506A5008273074 @default.
• W2990708506 hasAuthorship W2990708506A5014913190 @default.
• W2990708506 hasAuthorship W2990708506A5015953107 @default.
• W2990708506 hasAuthorship W2990708506A5016202197 @default.
• W2990708506 hasAuthorship W2990708506A5068524115 @default.
• W2990708506 hasAuthorship W2990708506A5073326633 @default.
• W2990708506 hasAuthorship W2990708506A5091459931 @default.
• W2990708506 hasBestOaLocation W29907085061 @default.
• W2990708506 hasConcept C112392421 @default.
• W2990708506 hasConcept C11960822 @default.
• W2990708506 hasConcept C126322002 @default.
• W2990708506 hasConcept C13373296 @default.
• W2990708506 hasConcept C137061746 @default.
• W2990708506 hasConcept C157333092 @default.
• W2990708506 hasConcept C170493617 @default.
• W2990708506 hasConcept C171958077 @default.
• W2990708506 hasConcept C202751555 @default.
• W2990708506 hasConcept C203014093 @default.
• W2990708506 hasConcept C2777575956 @default.
• W2990708506 hasConcept C2778690821 @default.
• W2990708506 hasConcept C2778886723 @default.
• W2990708506 hasConcept C2778923194 @default.
• W2990708506 hasConcept C42362537 @default.
• W2990708506 hasConcept C55493867 @default.
• W2990708506 hasConcept C71924100 @default.
• W2990708506 hasConcept C86803240 @default.

• next